International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

William Travis 1, * Elisabeth Brambilla 2 Masayuki Noguchi 3 Andrew Nicholson 4 Kim Geisinger 5 Yasushi Yatabe 6 David Beer 7 Charles Powell 8 Gregory Riely 9 Paul Van Schil 10 Kavita Garg 11 John Austin 12 Hisao Asamura 13 Valerie Rusch 14 Fred Hirsch 15 Giorgio Scagliotti 16 Tetsuya Mitsudomi 17 Rudolf Huber 18 Yuichi Ishikawa 19 James Jett 20 Montserrat Sanchez-Cespedes 21 Jean-Paul Sculier 22 Takashi Takahashi 23 Masahiro Tsuboi 24 Johan Vansteenkiste 25 Ignacio Wistuba 26 Pan-Chyr Yang 27 Denise Aberle 28 Christian Brambilla 29 Douglas Flieder 30 Wilbur Franklin 31 Adi Gazdar 32 Michael Gould 33 Philip Hasleton 34 Douglas Henderson 35 Bruce Johnson 36 David Johnson 37 Keith Kerr 38 Keiko Kuriyama 39 Jin Soo Lee 40 Vincent Miller 9 Iver Petersen 41 Victor Roggli 42 Rafael Rosell 43 Nagahiro Saijo 44 Erik Thunnissen 45 Ming Tsao 46 David Yankelewitz 47
* Auteur correspondant
29 INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon)
INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble, Clinique de pneumologie
Abstract : This new classification strategy is based on a multidisciplinary approach to diagnosis of lung adenocarcinoma that incorporates clinical, molecular, radiologic, and surgical issues, but it is primarily based on histology. This classification is intended to support clinical practice, and research investigation and clinical trials. As EGFR mutation is a validated predictive marker for response and progression-free survival with EGFR tyrosine kinase inhibitors in advanced lung adenocarcinoma, we recommend that patients with advanced adenocarcinomas be tested for EGFR mutation. This has implications for strategic management of tissue, particularly for small biopsies and cytology samples, to maximize high-quality tissue available for molecular studies. Potential impact for tumor, node, and metastasis staging include adjustment of the size T factor according to only the invasive component (1) pathologically in invasive tumors with lepidic areas or (2) radiologically by measuring the solid component of part-solid nodules.
Type de document :
Article dans une revue
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2011, 6 (2), pp.244-85. 〈10.1097/JTO.0b013e318206a221〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00561753
Contributeur : Christian Brambilla <>
Soumis le : mercredi 1 février 2012 - 07:00:04
Dernière modification le : mercredi 10 janvier 2018 - 10:12:02
Document(s) archivé(s) le : mercredi 2 mai 2012 - 02:20:09

Fichier

Travis_WD_Adenoca_Classificati...
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

U823 | UGA

Citation

William Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew Nicholson, Kim Geisinger, et al.. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.. Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2011, 6 (2), pp.244-85. 〈10.1097/JTO.0b013e318206a221〉. 〈inserm-00561753〉

Partager

Métriques

Consultations de la notice

616

Téléchargements de fichiers

5363